Studies in G12C and G12D KRAS-mutant lung cancer mouse models and organoids treated with KRAS inhibitors reveal that tumors invoke a lineage plasticity program to switch from adenocarcinoma to squamous via transcriptomic and epigenomic changes, modulating the response to KRAS inhibition [55]. This evidence concerns the gene KRAS and adenocarcinoma.